Banque Transatlantique SA Invests $106.71 Million in Eli Lilly and Company (NYSE:LLY)

Banque Transatlantique SA purchased a new stake in shares of Eli Lilly and Company (NYSE:LLY - Free Report) during the 4th quarter, according to the company in its most recent Form 13F filing with the SEC. The fund purchased 138,230 shares of the company's stock, valued at approximately $106,714,000. Eli Lilly and Company comprises approximately 2.5% of Banque Transatlantique SA's portfolio, making the stock its 12th biggest holding.

Other institutional investors have also recently made changes to their positions in the company. Principal Financial Group Inc. lifted its stake in Eli Lilly and Company by 5.3% during the third quarter. Principal Financial Group Inc. now owns 1,208,545 shares of the company's stock worth $1,070,698,000 after purchasing an additional 60,306 shares in the last quarter. Nordea Investment Management AB boosted its holdings in Eli Lilly and Company by 13.7% during the 4th quarter. Nordea Investment Management AB now owns 1,154,350 shares of the company's stock valued at $887,014,000 after acquiring an additional 138,835 shares during the period. Legacy Wealth Management LLC MS acquired a new position in Eli Lilly and Company in the 4th quarter valued at about $215,000. CWA Asset Management Group LLC increased its stake in Eli Lilly and Company by 11.9% during the fourth quarter. CWA Asset Management Group LLC now owns 6,794 shares of the company's stock worth $5,245,000 after purchasing an additional 724 shares during the period. Finally, Neville Rodie & Shaw Inc. boosted its stake in shares of Eli Lilly and Company by 0.6% in the fourth quarter. Neville Rodie & Shaw Inc. now owns 15,031 shares of the company's stock valued at $11,604,000 after purchasing an additional 97 shares during the period. Hedge funds and other institutional investors own 82.53% of the company's stock.

Analyst Upgrades and Downgrades

LLY has been the topic of a number of research reports. UBS Group reduced their target price on shares of Eli Lilly and Company from $1,100.00 to $1,050.00 and set a "buy" rating on the stock in a report on Friday. Morgan Stanley reiterated an "overweight" rating on shares of Eli Lilly and Company in a research note on Thursday, May 1st. The Goldman Sachs Group raised Eli Lilly and Company from a "neutral" rating to a "buy" rating and lowered their target price for the stock from $892.00 to $888.00 in a research note on Tuesday, April 8th. Truist Financial lifted their price objective on Eli Lilly and Company from $1,029.00 to $1,038.00 and gave the company a "buy" rating in a research note on Monday, February 3rd. Finally, Hsbc Global Res lowered shares of Eli Lilly and Company from a "strong-buy" rating to a "moderate sell" rating in a research note on Monday, April 28th. One investment analyst has rated the stock with a sell rating, two have assigned a hold rating and nineteen have assigned a buy rating to the company. According to data from MarketBeat, Eli Lilly and Company has an average rating of "Moderate Buy" and a consensus target price of $1,002.80.

Insider Transactions at Eli Lilly and Company

In other Eli Lilly and Company news, CAO Donald A. Zakrowski sold 1,000 shares of the stock in a transaction dated Thursday, March 13th. The shares were sold at an average price of $818.24, for a total value of $818,240.00. Following the completion of the transaction, the chief accounting officer now directly owns 5,840 shares of the company's stock, valued at approximately $4,778,521.60. This trade represents a 14.62 % decrease in their ownership of the stock. The sale was disclosed in a filing with the SEC, which is accessible through the SEC website. Company insiders own 0.14% of the company's stock.

Eli Lilly and Company Stock Performance

Eli Lilly and Company stock traded down $45.20 during mid-day trading on Tuesday, reaching $776.26. 5,961,205 shares of the company were exchanged, compared to its average volume of 3,485,577. The firm has a market cap of $735.69 billion, a PE ratio of 66.29, a price-to-earnings-growth ratio of 1.40 and a beta of 0.48. The company has a debt-to-equity ratio of 2.00, a quick ratio of 0.97 and a current ratio of 1.15. The firm's 50-day simple moving average is $823.48 and its two-hundred day simple moving average is $814.29. Eli Lilly and Company has a twelve month low of $677.09 and a twelve month high of $972.53.

Eli Lilly and Company (NYSE:LLY - Get Free Report) last announced its quarterly earnings data on Thursday, May 1st. The company reported $3.34 earnings per share (EPS) for the quarter, missing the consensus estimate of $4.64 by ($1.30). Eli Lilly and Company had a net margin of 23.51% and a return on equity of 85.24%. The firm had revenue of $12.73 billion during the quarter, compared to analyst estimates of $12.77 billion. During the same period in the prior year, the firm posted $2.58 earnings per share. The business's quarterly revenue was up 45.2% compared to the same quarter last year. Equities analysts predict that Eli Lilly and Company will post 23.48 earnings per share for the current fiscal year.

Eli Lilly and Company Announces Dividend

The firm also recently announced a quarterly dividend, which will be paid on Tuesday, June 10th. Shareholders of record on Friday, May 16th will be given a dividend of $1.50 per share. This represents a $6.00 annualized dividend and a yield of 0.77%. The ex-dividend date is Friday, May 16th. Eli Lilly and Company's payout ratio is 48.82%.

Eli Lilly and Company Company Profile

Eli Lilly and Company discovers, develops, and markets human pharmaceuticals worldwide. The company offers Basaglar, Humalog, Humalog Mix 75/25, Humalog U-100, Humalog U-200, Humalog Mix 50/50, insulin lispro, insulin lispro protamine, insulin lispro mix 75/25, Humulin, Humulin 70/30, Humulin N, Humulin R, and Humulin U-500 for diabetes; Jardiance, Mounjaro, and Trulicity for type 2 diabetes; and Zepbound for obesity.